207 related articles for article (PubMed ID: 29159332)
1. A biomaterial screening approach reveals microenvironmental mechanisms of drug resistance.
Schwartz AD; Barney LE; Jansen LE; Nguyen TV; Hall CL; Meyer AS; Peyton SR
Integr Biol (Camb); 2017 Dec; 9(12):912-924. PubMed ID: 29159332
[TBL] [Abstract][Full Text] [Related]
2. Potent in vitro and in vivo activity of sorafenib in multiple myeloma: induction of cell death, CD138-downregulation and inhibition of migration through actin depolymerization.
Udi J; Schüler J; Wider D; Ihorst G; Catusse J; Waldschmidt J; Schnerch D; Follo M; Wäsch R; Engelhardt M
Br J Haematol; 2013 Apr; 161(1):104-16. PubMed ID: 23384035
[TBL] [Abstract][Full Text] [Related]
3. Sorafenib resistance and JNK signaling in carcinoma during extracellular matrix stiffening.
Nguyen TV; Sleiman M; Moriarty T; Herrick WG; Peyton SR
Biomaterials; 2014 Jul; 35(22):5749-59. PubMed ID: 24726537
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of acquired-resistance hepatocellular carcinoma cell growth by combining sorafenib with phosphoinositide 3-kinase and rat sarcoma inhibitor.
Wu CH; Wu X; Zhang HW
J Surg Res; 2016 Dec; 206(2):371-379. PubMed ID: 27884331
[TBL] [Abstract][Full Text] [Related]
5. Exosomes derived from HCC cells induce sorafenib resistance in hepatocellular carcinoma both in vivo and in vitro.
Qu Z; Wu J; Wu J; Luo D; Jiang C; Ding Y
J Exp Clin Cancer Res; 2016 Sep; 35(1):159. PubMed ID: 27716356
[TBL] [Abstract][Full Text] [Related]
6. Pharmacologic inhibition of MEK signaling prevents growth of canine hemangiosarcoma.
Andersen NJ; Nickoloff BJ; Dykema KJ; Boguslawski EA; Krivochenitser RI; Froman RE; Dawes MJ; Baker LH; Thomas DG; Kamstock DA; Kitchell BE; Furge KA; Duesbery NS
Mol Cancer Ther; 2013 Sep; 12(9):1701-14. PubMed ID: 23804705
[TBL] [Abstract][Full Text] [Related]
7. Notch3 inhibition enhances sorafenib cytotoxic efficacy by promoting GSK3b phosphorylation and p21 down-regulation in hepatocellular carcinoma.
Giovannini C; Baglioni M; Baron Toaldo M; Ventrucci C; D'Adamo S; Cipone M; Chieco P; Gramantieri L; Bolondi L
Oncotarget; 2013 Oct; 4(10):1618-31. PubMed ID: 24113128
[TBL] [Abstract][Full Text] [Related]
8. TLR3 agonist and Sorafenib combinatorial therapy promotes immune activation and controls hepatocellular carcinoma progression.
Ho V; Lim TS; Lee J; Steinberg J; Szmyd R; Tham M; Yaligar J; Kaldis P; Abastado JP; Chew V
Oncotarget; 2015 Sep; 6(29):27252-66. PubMed ID: 26287667
[TBL] [Abstract][Full Text] [Related]
9. Differential inhibitory effects of two Raf-targeting drugs, sorafenib and PLX4720, on the growth of multidrug-resistant cells.
Eum KH; Ahn SK; Kang H; Lee M
Mol Cell Biochem; 2013 Jan; 372(1-2):65-74. PubMed ID: 22941213
[TBL] [Abstract][Full Text] [Related]
10. Perifosine and sorafenib combination induces mitochondrial cell death and antitumor effects in NOD/SCID mice with Hodgkin lymphoma cell line xenografts.
Locatelli SL; Giacomini A; Guidetti A; Cleris L; Mortarini R; Anichini A; Gianni AM; Carlo-Stella C
Leukemia; 2013 Aug; 27(8):1677-87. PubMed ID: 23360848
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA-122 confers sorafenib resistance to hepatocellular carcinoma cells by targeting IGF-1R to regulate RAS/RAF/ERK signaling pathways.
Xu Y; Huang J; Ma L; Shan J; Shen J; Yang Z; Liu L; Luo Y; Yao C; Qian C
Cancer Lett; 2016 Feb; 371(2):171-81. PubMed ID: 26655273
[TBL] [Abstract][Full Text] [Related]
12. Synergistic anti-proliferative effect of metformin and sorafenib on growth of anaplastic thyroid cancer cells and their stem cells.
Chen G; Nicula D; Renko K; Derwahl M
Oncol Rep; 2015 Apr; 33(4):1994-2000. PubMed ID: 25683253
[TBL] [Abstract][Full Text] [Related]
13. Early decline in serum phospho-CSE1L levels in vemurafenib/sunitinib-treated melanoma and sorafenib/lapatinib-treated colorectal tumor xenografts.
Lee WR; Shen SC; Shih YH; Chou CL; Tseng JT; Chin SY; Liu KH; Chen YC; Jiang MC
J Transl Med; 2015 Jun; 13():191. PubMed ID: 26070816
[TBL] [Abstract][Full Text] [Related]
14. Oncogene mimicry as a mechanism of primary resistance to BRAF inhibitors.
Sos ML; Levin RS; Gordan JD; Oses-Prieto JA; Webber JT; Salt M; Hann B; Burlingame AL; McCormick F; Bandyopadhyay S; Shokat KM
Cell Rep; 2014 Aug; 8(4):1037-48. PubMed ID: 25127139
[TBL] [Abstract][Full Text] [Related]
15. Synergistic interactions between sorafenib and everolimus in pancreatic cancer xenografts in mice.
Pawaskar DK; Straubinger RM; Fetterly GJ; Hylander BH; Repasky EA; Ma WW; Jusko WJ
Cancer Chemother Pharmacol; 2013 May; 71(5):1231-40. PubMed ID: 23455452
[TBL] [Abstract][Full Text] [Related]
16. Adaptation to TKI Treatment Reactivates ERK Signaling in Tyrosine Kinase-Driven Leukemias and Other Malignancies.
Bruner JK; Ma HS; Li L; Qin ACR; Rudek MA; Jones RJ; Levis MJ; Pratz KW; Pratilas CA; Small D
Cancer Res; 2017 Oct; 77(20):5554-5563. PubMed ID: 28923853
[TBL] [Abstract][Full Text] [Related]
17. Flavopiridol synergizes with sorafenib to induce cytotoxicity and potentiate antitumorigenic activity in EGFR/HER-2 and mutant RAS/RAF breast cancer model systems.
Nagaria TS; Williams JL; Leduc C; Squire JA; Greer PA; Sangrar W
Neoplasia; 2013 Aug; 15(8):939-51. PubMed ID: 23908594
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic potential of MEK inhibition in acute myelogenous leukemia: rationale for "vertical" and "lateral" combination strategies.
Ricciardi MR; Scerpa MC; Bergamo P; Ciuffreda L; Petrucci MT; Chiaretti S; Tavolaro S; Mascolo MG; Abrams SL; Steelman LS; Tsao T; Marchetti A; Konopleva M; Del Bufalo D; Cognetti F; Foà R; Andreeff M; McCubrey JA; Tafuri A; Milella M
J Mol Med (Berl); 2012 Oct; 90(10):1133-44. PubMed ID: 22399013
[TBL] [Abstract][Full Text] [Related]
19. Allosteric MEK1/2 inhibitor refametinib (BAY 86-9766) in combination with sorafenib exhibits antitumor activity in preclinical murine and rat models of hepatocellular carcinoma.
Schmieder R; Puehler F; Neuhaus R; Kissel M; Adjei AA; Miner JN; Mumberg D; Ziegelbauer K; Scholz A
Neoplasia; 2013 Oct; 15(10):1161-71. PubMed ID: 24204195
[TBL] [Abstract][Full Text] [Related]
20. Mathematical modelling unveils the essential role of cellular phosphatases in the inhibition of RAF-MEK-ERK signalling by sorafenib in hepatocellular carcinoma cells.
Saidak Z; Giacobbi AS; Louandre C; Sauzay C; Mammeri Y; Galmiche A
Cancer Lett; 2017 Apr; 392():1-8. PubMed ID: 28161506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
